Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study evaluated the efficacy and safety of a 5% minoxidil topical foam without propylene glycol in men with androgenic alopecia.

The study observed unexpected blue fluorescence in urine linked to salicylate metabolite presence, suggesting "aspirin addiction" in patients with unexplained hair loss, potentially tied to chronic disease or hair production interference.

This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.

This study found that over half of participants used complementary and alternative medicine, with nearly half reporting satisfactory results, while almost one-fifth did not take their prescribed medications.

In this study, ALRV5XR treatment significantly increased terminal hair density in men with androgenetic alopecia after 24 weeks, while also decreasing vellus hair density, and was well tolerated without adverse events, suggesting its potential efficacy over standard therapies.

In this study involving dogs, co-mingling of mange-infested and healthy dogs proved to be the most effective method for transmitting mange, although placing healthy dogs in kennels recently vacated by infested dogs also led to successful transmission.

In this clinical trial, supplementation with Lambdapil® Anti Hair Loss capsules for 6 months significantly improved hair resistance and volume in women and increased the anagen/telogen hair ratio in men, indicating enhanced hair growth compared to the placebo group.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

Cinainu is effective and safe for treating children's alopecia areata.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

In this study, substituting Sangyod rice flour for wheat flour in butter cakes improved nutritional profiles and maintained sensory qualities, with 50% substitution showing the best balance, supporting local agriculture and potentially leading to healthier bakery options.

This study found that treating asymptomatic or mild COVID-19 with cepharanthine did not significantly reduce the time to a negative test result, though 60 mg/day showed a non-significant trend needing further validation.

Salivary vitamin D and IL-6 could help diagnose and manage non-scarring alopecia.

In this animal study, researchers found that daily oral intake of salmon nasal cartilage proteoglycan enhanced hair growth in mice, potentially through a signaling pathway that stimulates specific growth factors in human follicle cells.

In this survey study, dermatologists in the Aseer region of Saudi Arabia generally exhibited good knowledge of isotretinoin's ocular side effects like dry eye and contact lens intolerance, but their practices varied regarding patient education and management of these effects.

This study reviewed the safety of JAK inhibitors for alopecia areata, finding that common side effects included headache and acne, with varying risks for respiratory infections and no increased risk of serious adverse events.

In this study, grape seed oil was found to be the most effective herbal oil for improving gloss and reducing fractures in various hair types.

In this study, researchers reported that a newly developed interferon-γ release assay for cell-mediated immunity to SARS-CoV-2 nucleocapsid peptides demonstrated high sensitivity and specificity, making it a robust tool for routine diagnostic tests and potentially useful in predicting clinical outcomes after pathogen re-exposure.

This research reported that KDML105 bran extract demonstrated antioxidant activities, reduced nitric oxide production, and influenced gene expression related to the hair cycle in cultured dermal papilla cells, suggesting potential as an anti-hair loss agent by supporting the anagen phase and angiogenesis.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

This report describes a case of alopecia areata returning as AA universalis in a 63-year-old woman after receiving the SARS-CoV-2 vaccine, following a 32-year remission.

In this study, the COVID-19 pandemic was associated with increased diagnoses of acne and telogen effluvium, particularly among patients with COVID-19, at a New York City hospital system.

This study describes the presence of SARS-CoV-2 in hair follicles from a patient with early-onset post-COVID hair loss, suggesting a potential direct impact of the virus on hair physiology.

This report describes a case where an elderly woman developed alopecia areata shortly after receiving the Pfizer COVID-19 vaccine, which was effectively treated with topical tacrolimus and minoxidil.

This study found that SAMiRNA-AR68, a nanomedicine targeting androgen receptor mRNA, increased hair counts in androgenetic alopecia patients with no observed side effects.

This study suggests that women with polycystic ovary syndrome may have an increased risk of COVID-19-related cardiac and renal complications, and that weight loss through lifestyle changes could help reduce these risks.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

This review concludes that global literature supports the lipidosterolic extract of Serenoa repens as efficacious and safe for treating lower urinary tract symptoms, with some studies showing equivalence to common pharmacologic agents.

This study reports that sacituzumab govitecan achieved a 33.3% overall response rate in patients with metastatic triple-negative breast cancer who had prior treatments, with a median response duration of 7.7 months.